Prognostic value of c-Met overexpression in pancreatic adenocarcinoma: a meta-analysis
Metrics: PDF 400 views | HTML 755 views | ?
Jung Han Kim1, Hyeong Su Kim1, Bum Jun Kim1,2, Jin Lee3 and Hyun Joo Jang3
1Division of Hemato-Oncology, Department of Internal Medicine, Kangnam Sacred-Heart Hospital, Hallym University Medical Center, Hallym University College of Medicine, Seoul 07441, Republic of Korea
2Department of Internal Medicine, National Army Capital Hospital, The Armed Forces Medical Command, Sungnam 13574, Republic of Korea
3Division of Gastroenterology, Department of Internal Medicine, Dongtan Sacred-Heart Hospital, Hallym University Medical Center, Hallym University College of Medicine, Hwasung 18450, Republic of Korea
Jung Han Kim, email: email@example.com
Hyun Joo Jang, email: firstname.lastname@example.org
Keywords: c-Met, pancreatic cancer, prognostic value, meta-analysis
Received: June 01, 2017 Accepted: August 07, 2017 Published: August 22, 2017
The overexpression of c-Met protein has been detected in pancreatic adenocarcinoma (PAC). However, its prognostic impact remains unclear. We performed this meta-analysis to evaluate the prognostic value of c-Met overexpression in PAC. A systematic computerized search of the electronic databases such as PubMed, Embase, and Google Scholar was carried out. From 5 studies, 423 patients who underwent surgical resection for PAC were included in the meta-analysis. Compared with patients with PAC showing low c-Met expression, patients with c-Met-high tumor had significantly worse disease-free survival (hazard ratio = 1.94 [95% confidence interval, 1.46–2.56], P = 0.00001) and overall survival (hazard ratio = 1.86 [95% confidence interval, 1.19–2.91], P = 0.006). In conclusion, this meta-analysis demonstrates that c-Met overexpression is a significant prognostic marker for poor survival in patients who underwent surgical resection for PAC.
All site content, except where otherwise noted, is licensed under a Creative Commons Attribution 3.0 License.